VHH Antibodies, primarily derived from Camelids (Camels, Llamas, Alpacas), are only 13 to 15 kDa in size, significantly smaller than full-length IgG antibodies (150-160 kDa) and other antibody fragments (Fab ~50 kDa, scFv ~25 kDa). Consequently, VHH Antibodies exhibit superior stability and penetration capabilities, enabling broad applications in Academic Research, Clinical Diagnostics, Therapeutic Antibody Development, and Cell Therapy. VHH antibodies are easily produced at scale in E. coli and possess unique antigen-binding properties.

KMD Bioscience possesses an experienced team for Recombinant Antibody Preparation, capable of producing ideal VHH Antibodies. Our high-quality VHH Antibodies meet client needs in areas such as Cryptic Epitope Detection, Enzyme Active Site Binding, Diagnostic Imaging, and Viral Neutralization. We primarily generate VHHs by immunizing Alpacas and screening the desired clones using Phage Display Technology. Subsequently, we produce VHHs with high Sensitivity, Specificity, and Affinity using E. coli or Mammalian Expression Systems.

Recombinant and Hybridoma-derived Antibodies are widely used clinically for diagnosing and treating various diseases. However, these animal-derived antibodies often exhibit high immunogenicity. When used therapeutically, they are rapidly cleared from circulation and can trigger systemic inflammatory responses, compromising their efficacy. While VHHs originate from Camelids, they also possess inherent immunogenicity, limiting their therapeutic effectiveness.

Antibody Humanization Technology can reduce the immunogenicity of recombinant antibodies. KMD Bioscience offers expert humanization strategies for VHH Antibodies. Our approach involves introducing the human immunoglobulin heavy chain locus (excluding the CH1 domain) into mice with knocked-out endogenous immunoglobulin genes. Following antigen immunization, these mice produce antibodies consisting solely of heavy chains. Our optimized VHH Antibodies exhibit extremely low immunogenicity, comparable to human antibodies, while preserving their antigen affinity and specificity. Our scientific team provides professional and effective Humanized Antibody Sequence Prediction, enabling the production of VHHs that maintain high specificity and affinity for the target antigen while significantly or completely eliminating immunogenicity in humans. To validate the efficacy of humanized VHH Antibodies, we characterize them using techniques including ELISA, WB, Immunoprecipitation, Flow Cytometry, Immunohistochemistry, IC50 Determination, and Endotoxin Testing, ensuring their functionality.